All In Biotech

NDA 217225 · Astellas

Izervay

Avacincaptad Pegol Sodium · Intravitreal

NovelBreakthrough therapyPriority review

CDER novel approval, Aug 4, 2023: To treat geographic atrophy secondary to age-related macular degeneration

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Aug 4, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

13

3 Phase 3, 1 recruiting

FAERS reports

352

141 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 3, 2026.

IZERVAY ® is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) ( 1 ).

Mechanism: Avacincaptad pegol is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 12, 2025 Supplement 1 · Efficacy LetterLabel
  • Aug 4, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLetterLabelReview
1 products under this application
  • IZERVAY · AVACINCAPTAD PEGOL SODIUM EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) · SOLUTION, INTRAVITREAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Avacincaptad Pegol" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • visual impairment26
  • intercepted product preparation error25
  • eye pain24
  • no adverse event24
  • needle issue23
  • off label use22
  • vision blurred22
  • syringe issue18
  • endophthalmitis16
  • product temperature excursion issue16
  • choroidal neovascularisation15
  • intraocular pressure increased15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20235
2024110
2025114
2026123

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Izervay (Avacincaptad PEGol Sodium/PF)

2024 spending

$3.9M

Beneficiaries

343

1,353 claims

Per beneficiary

$11,413

$20,900.99 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$216,001
2024$3,914,756

Part B: Izervay (Avacincaptad Pegol Sodium/PF) · HCPCS J2782

2024 spending

$190M

Beneficiaries

18,308

73,172 claims

Per beneficiary

$10,398

2024 ASP limit $110.43 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$190,365,233

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Astellas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.